These results suggest that prophylactic treatment with a combination of IL-2 IC and tacrolimus does not have an additive effect on proteinuria in SLE-like GVHD, whereas IL-2 ameliorates proteinuria. This evidence concerns the gene IL2 and graft versus host disease.